SCM
NBSE

Stonepine Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Stonepine Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,487
Closed -$396K – 34
2021
Q3 		$396K Buy
5,487
+3,933
+253% +$301K 0.18% 27
2021
Q2 		$149K Buy
+1,554
New +$172K 0.08% 23

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonepine Capital Management's NBSE Position: Q4 2021 in Review

Stonepine Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2021, closing a stake of 5,487 shares — an estimated $396K sold.

Stonepine Capital Management first reported a position in NBSE in Q2 2021 and held it in 2 quarters. The position peaked at $396K in Q3 2021. 45 funds tracked by Wall St. Rank hold NBSE as of Q4 2021.

  • Stonepine Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Stonepine Capital Management sold 5,487 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $396K.
  • Stonepine Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Stonepine Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $396K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Stonepine Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.